Laura Elizabeth Gould
Research Subjects
Laura Elizabeth Gould has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- John Taylor Jenkins
St Marks Hospital, Complex Cancer Clinic , London
7 shared publications - Edward Tobias Pring
George Davies Research Fellowship, St Mark's Hospital, London, UK.
6 shared publications - Ioanna Drami
Complex Cancer Clinic St Mark′s‐The National Bowel Hospital Harrow London UK
6 shared publications Edward T. Pring
St Mark's Academic Institute, St Mark's- The National Bowel Hospital, Harrow, UK
3 shared publicationsJohn T. Jenkins
St Mark's Academic Institute, St Mark's Hospital, United Kingdom; Imperial College London, United Kingdom
3 shared publications- Phillip Lung
Imperial College London, London, UK
3 shared publications
Latest Publications
- Open Access
- 5 November 2025
- Published by Wiley in Journal of Surgical Oncology
- Vol. 132 (8) , 1399-1406
Gluteal Flap Reconstruction Following Complex Rectal Cancer Surgery: A Large Consecutive Series of Perineal Wounds Exploring Risk Factors for Complications
Aim: To determine whether high complexity pelvic exenterations alter perineal wound morbidity and to assess risk factors for perineal flap complications following complex rectal cancer surgery. Methods: A retrospective analysis of consecutive adults undergoing complex rectal cancer resections with immediate gluteal flap perineal reconstruction between January 2013‐July 2021 at a tertiary referral centre. Conventional complex cancer resections were compared with “high complexity” exenterations, including en bloc sacrectomy and extended lateral pelvic side wall excision. Primary outcomes were short‐term (wound infection, necrosis, dehiscence) and long‐term (sinus, fistula, hernia) perineal flap complications. Results: We identified 194 patients (median 56 years, 60% male) with gluteal flap reconstructions; 163 (84%) for advanced or recurrent rectal cancer. Gluteal artery perforator flaps were predominantly used (176, 92%). Wound infections were more common in the conventional group (23.2% vs. 6.3%, p = 0.001), but no other differences in complications were observed between groups. Obesity (HR 2.70, 95% CI 1.22–5.97, p = 0.014) and total pelvic exenteration (HR 2.13, 95% CI 1.07–4.23, p = 0.031) were associated with short‐term complications. Age over 65 years predicted readmission/reoperation (HR 2.66, 95%CI 1.07–6.6, p = 0.040). Ureteric/ileal conduit leaks were associated with long‐term complications (HR 3.37, 95% CI 1.21–9.34, p = 0.024). No flap losses occurred. Conclusion: Gluteal fasciocutaneous perforator flaps provide reliable perineal reconstruction after complex rectal cancer surgery. The extent of surgery and resulting defect size did not significantly influence perineal wound complication rates.
- 5 November 2025
- Published by Wiley in Journal of Surgical Oncology
- Vol. 132 (8) , 1399-1406
Open AccessGluteal Flap Reconstruction Following Complex Rectal Cancer Surgery: A Large Consecutive Series of Perineal Wounds Exploring Risk Factors for Complications
Aim: To determine whether high complexity pelvic exenterations alter perineal wound morbidity and to assess risk factors for perineal flap complications following complex rectal cancer surgery. Methods: A retrospective analysis of consecutive adults undergoing complex rectal cancer resections with immediate gluteal flap perineal reconstruction between January 2013‐July 2021 at a tertiary referral centre. Conventional complex cancer resections were compared with “high complexity” exenterations, including en bloc sacrectomy and extended lateral pelvic side wall excision. Primary outcomes were short‐term (wound infection, necrosis, dehiscence) and long‐term (sinus, fistula, hernia) perineal flap complications. Results: We identified 194 patients (median 56 years, 60% male) with gluteal flap reconstructions; 163 (84%) for advanced or recurrent rectal cancer. Gluteal artery perforator flaps were predominantly used (176, 92%). Wound infections were more common in the conventional group (23.2% vs. 6.3%, p = 0.001), but no other differences in complications were observed between groups. Obesity (HR 2.70, 95% CI 1.22–5.97, p = 0.014) and total pelvic exenteration (HR 2.13, 95% CI 1.07–4.23, p = 0.031) were associated with short‐term complications. Age over 65 years predicted readmission/reoperation (HR 2.66, 95%CI 1.07–6.6, p = 0.040). Ureteric/ileal conduit leaks were associated with long‐term complications (HR 3.37, 95% CI 1.21–9.34, p = 0.024). No flap losses occurred. Conclusion: Gluteal fasciocutaneous perforator flaps provide reliable perineal reconstruction after complex rectal cancer surgery. The extent of surgery and resulting defect size did not significantly influence perineal wound complication rates.
- Open Access
- 28 April 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (11) , 5103-5123
MRI radiomics prediction modelling for pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review and meta-analysis
Purpose: Predicting response to neoadjuvant therapy in locally advanced rectal cancer (LARC) is challenging. Organ preservation strategies can be offered to patients with complete clinical response. We aim to evaluate MRI-derived radiomics models in predicting complete pathological response (pCR). Methods: Search included MEDLINE, Embase and Cochrane Central Register of Controlled Trials (CENTRAL) and Cochrane Database of Systematic Reviews (CDSR) for studies published before 1st February 2024. The Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) and Radiomics Quality Score (RQS) tools were used to assess quality of included study. The research protocol was registered in PROSPERO (CRD42024512865). We calculated pooled area under the receiver operating characteristic curve (AUC) using a random-effects model. To compare AUC between subgroups the Hanley & McNeil test was performed. Results: Forty-four eligible studies (12,714 patients) were identified for inclusion in the systematic review. We selected thirty-five studies including 10,543 patients for meta-analysis. The pooled AUC for MRI radiomics predicted pCR in LARC was 0.87 (95% CI 0.84–0.89). In the subgroup analysis 3 T MRI field intensity had higher pooled AUC 0.9 (95% CI 0.87–0.94) than 1.5 T pooled AUC 0.82 (95% CI 0.80–0.83) p < 0.001. Asian ethnicity had higher pooled AUC 0.9 (95% CI 0.87–0.93) than non-Asian pooled AUC 0.8 (95% CI 0.75–0.84) p < 0.001. Conclusion: We have demonstrated that 3 T MRI field intensity provides a superior predictive performance. The role of ethnicity on radiomics features needs to be explored in future studies. Further research in the field of MRI radiomics is important as accurate prediction for pCR can lead to organ preservation strategy in LARC. Graphical
- 28 April 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (11) , 5103-5123
Open AccessMRI radiomics prediction modelling for pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review and meta-analysis
Purpose: Predicting response to neoadjuvant therapy in locally advanced rectal cancer (LARC) is challenging. Organ preservation strategies can be offered to patients with complete clinical response. We aim to evaluate MRI-derived radiomics models in predicting complete pathological response (pCR). Methods: Search included MEDLINE, Embase and Cochrane Central Register of Controlled Trials (CENTRAL) and Cochrane Database of Systematic Reviews (CDSR) for studies published before 1st February 2024. The Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) and Radiomics Quality Score (RQS) tools were used to assess quality of included study. The research protocol was registered in PROSPERO (CRD42024512865). We calculated pooled area under the receiver operating characteristic curve (AUC) using a random-effects model. To compare AUC between subgroups the Hanley & McNeil test was performed. Results: Forty-four eligible studies (12,714 patients) were identified for inclusion in the systematic review. We selected thirty-five studies including 10,543 patients for meta-analysis. The pooled AUC for MRI radiomics predicted pCR in LARC was 0.87 (95% CI 0.84–0.89). In the subgroup analysis 3 T MRI field intensity had higher pooled AUC 0.9 (95% CI 0.87–0.94) than 1.5 T pooled AUC 0.82 (95% CI 0.80–0.83) p < 0.001. Asian ethnicity had higher pooled AUC 0.9 (95% CI 0.87–0.93) than non-Asian pooled AUC 0.8 (95% CI 0.75–0.84) p < 0.001. Conclusion: We have demonstrated that 3 T MRI field intensity provides a superior predictive performance. The role of ethnicity on radiomics features needs to be explored in future studies. Further research in the field of MRI radiomics is important as accurate prediction for pCR can lead to organ preservation strategy in LARC. Graphical
- Open Access
A Scoping Review of the Implications and Applications of Body Composition Assessment in Locally Advanced and Locally Recurrent Rectal Cancer
Background: A strong body of evidence exists demonstrating deleterious relationships between abnormal body composition (BC) and outcomes in non-complex colorectal cancer. Complex rectal cancer (RC) includes locally advanced and locally recurrent tumours. This scoping review aims to summarise the current evidence examining BC in complex RC. Methods: A literature search was performed on Ovid MEDLINE, EMBASE, and Cochrane databases. Original studies examining BC in adult patients with complex RC were included. Two authors undertook screening and full-text reviews. Results: Thirty-five studies were included. Muscle quantity was the most commonly studied BC metric, with sarcopenia appearing to predict mortality, recurrence, neoadjuvant therapy outcomes, and postoperative complications. In particular, 10 studies examined relationships between BC and neoadjuvant therapy response, with six showing a significant association with sarcopenia. Only one study examined interventions for improving BC in patients with complex RC, and only one study specifically examined patients undergoing pelvic exenteration. Marked variation was also observed in terms of how BC was quantified, both in terms of anatomical location and how cut-off values were defined. Conclusions: Sarcopenia appears to predict mortality and recurrence in complex RC. An opportunity exists for a meta-analysis examining poorer BC and neoadjuvant therapy outcomes. There is a paucity of studies examining interventions for poor BC. Further research examining BC specifically in patients undergoing pelvic exenteration surgery is also lacking. Pitfalls identified include variances in how BC is measured on computed tomography and whether external cut-off values for muscle and adipose tissue are appropriate for a particular study population.
Open AccessA Scoping Review of the Implications and Applications of Body Composition Assessment in Locally Advanced and Locally Recurrent Rectal Cancer
Background: A strong body of evidence exists demonstrating deleterious relationships between abnormal body composition (BC) and outcomes in non-complex colorectal cancer. Complex rectal cancer (RC) includes locally advanced and locally recurrent tumours. This scoping review aims to summarise the current evidence examining BC in complex RC. Methods: A literature search was performed on Ovid MEDLINE, EMBASE, and Cochrane databases. Original studies examining BC in adult patients with complex RC were included. Two authors undertook screening and full-text reviews. Results: Thirty-five studies were included. Muscle quantity was the most commonly studied BC metric, with sarcopenia appearing to predict mortality, recurrence, neoadjuvant therapy outcomes, and postoperative complications. In particular, 10 studies examined relationships between BC and neoadjuvant therapy response, with six showing a significant association with sarcopenia. Only one study examined interventions for improving BC in patients with complex RC, and only one study specifically examined patients undergoing pelvic exenteration. Marked variation was also observed in terms of how BC was quantified, both in terms of anatomical location and how cut-off values were defined. Conclusions: Sarcopenia appears to predict mortality and recurrence in complex RC. An opportunity exists for a meta-analysis examining poorer BC and neoadjuvant therapy outcomes. There is a paucity of studies examining interventions for poor BC. Further research examining BC specifically in patients undergoing pelvic exenteration surgery is also lacking. Pitfalls identified include variances in how BC is measured on computed tomography and whether external cut-off values for muscle and adipose tissue are appropriate for a particular study population.
- 26 June 2023
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (11) , 106971
Pathological determinants of outcome following resection of locally advanced or locally recurrent rectal cancer
- 26 June 2023
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (11) , 106971
Pathological determinants of outcome following resection of locally advanced or locally recurrent rectal cancer
- 1 August 2022
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 104, 106738
A systematic review of the pathological determinants of outcome following resection by pelvic exenteration of locally advanced and locally recurrent rectal cancer
Despite multimodal therapy 5-15% of patients who undergo resection for advanced rectal cancer (LARC) will develop local recurrence. Management of locally recurrent rectal cancer (LRRC) presents a significant therapeutic challenge and even with modern exenterative surgery, 5-year survival rates are poor at 25-50%. High rates of local and systemic recurrence in this cohort are reflective of the likely biological aggressiveness of these tumour types. This review aims to appraise the current literature identifying pathological factors associated with survival and tumour recurrence in patients undergoing exenterative surgery. A systematic review was carried out searching MEDLINE, EMBASE and COCHRANE Trials database for all studies assessing pathological factors influencing survival following pelvic exenteration for LARC or LRRC from 2010 to July 2021 following PRISMA guidelines. Risk of bias was assessed using QUIPS tool. Nine cohort studies met inclusion criteria, reporting outcomes for 2864 patients. Meta-analysis was not possible due to significant heterogeneity of reported outcomes. Resection margin status and nodal disease were the most commonly reported factors. A positive resection margin was demonstrated to be a negative prognostic marker in six studies. Involved lymph nodes and lymphovascular invasion also appear to be negative prognostic markers with tumour stage to be of lesser importance. No studies assessed other adverse tumour features that would not otherwise be included in a standard histopathology report. Pathological resection margin status is widely demonstrated to influence disease free and overall survival following pelvic exenteration for rectal cancer. With increasing R0 rates, other adverse tumour features must be explored to help elucidate differences in survival and potentially guide tailored oncological treatment.
- 1 August 2022
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 104, 106738
A systematic review of the pathological determinants of outcome following resection by pelvic exenteration of locally advanced and locally recurrent rectal cancer
Despite multimodal therapy 5-15% of patients who undergo resection for advanced rectal cancer (LARC) will develop local recurrence. Management of locally recurrent rectal cancer (LRRC) presents a significant therapeutic challenge and even with modern exenterative surgery, 5-year survival rates are poor at 25-50%. High rates of local and systemic recurrence in this cohort are reflective of the likely biological aggressiveness of these tumour types. This review aims to appraise the current literature identifying pathological factors associated with survival and tumour recurrence in patients undergoing exenterative surgery. A systematic review was carried out searching MEDLINE, EMBASE and COCHRANE Trials database for all studies assessing pathological factors influencing survival following pelvic exenteration for LARC or LRRC from 2010 to July 2021 following PRISMA guidelines. Risk of bias was assessed using QUIPS tool. Nine cohort studies met inclusion criteria, reporting outcomes for 2864 patients. Meta-analysis was not possible due to significant heterogeneity of reported outcomes. Resection margin status and nodal disease were the most commonly reported factors. A positive resection margin was demonstrated to be a negative prognostic marker in six studies. Involved lymph nodes and lymphovascular invasion also appear to be negative prognostic markers with tumour stage to be of lesser importance. No studies assessed other adverse tumour features that would not otherwise be included in a standard histopathology report. Pathological resection margin status is widely demonstrated to influence disease free and overall survival following pelvic exenteration for rectal cancer. With increasing R0 rates, other adverse tumour features must be explored to help elucidate differences in survival and potentially guide tailored oncological treatment.
- 1 December 2021
- Published by Elsevier in Clinical Oncology
- Vol. 33 (12) , e540-e552
Body Composition and Dose-limiting Toxicity in Colorectal Cancer Chemotherapy Treatment; a Systematic Review of the Literature. Could Muscle Mass be the New Body Surface Area in Chemotherapy Dosing?
- 1 December 2021
- Published by Elsevier in Clinical Oncology
- Vol. 33 (12) , e540-e552
Body Composition and Dose-limiting Toxicity in Colorectal Cancer Chemotherapy Treatment; a Systematic Review of the Literature. Could Muscle Mass be the New Body Surface Area in Chemotherapy Dosing?
- Open Access
- 15 September 2021
- Published by Springer Nature in Trials
- Vol. 22 (1) , 1-12
BiCyCLE NMES—neuromuscular electrical stimulation in the perioperative treatment of sarcopenia and myosteatosis in advanced rectal cancer patients: design and methodology of a phase II randomised controlled trial
Background: Colorectal cancer is associated with secondary sarcopenia (muscle loss) and myosteatosis (fatty infiltration of muscle) and patients who exhibit these host characteristics have poorer outcomes following surgery. Furthermore, patients, who undergo curative advanced rectal cancer surgery such as pelvic exenteration, are at risk of skeletal muscle loss due to immobility, malnutrition and a post-surgical catabolic state. Neuromuscular electrical stimulation (NMES) may be a feasible adjunctive treatment to help ameliorate these adverse side-effects. Hence, the purpose of this study is to investigate NMES as an adjunctive pre- and post-operative treatment for rectal cancer patients in the radical pelvic surgery setting and to provide early indicative evidence of efficacy in relation to key health outcomes.Method: In a phase II, double-blind, randomised controlled study, 58 patients will be recruited and randomised (1:1) to either a treatment (NMES plus standard care) or placebo (sham-NMES plus standard care) group. The intervention will begin 2 weeks pre-operatively and continue for 8 weeks after exenterative surgery. The primary outcome will be change in mean skeletal muscle attenuation, a surrogate marker of myosteatosis. Sarcopenia, quality of life, inflammatory status and cancer specific outcomes will also be assessed.Discussion: This phase II randomised controlled trial will provide important preliminary evidence of the potential for this adjunctive treatment. It will provide guidance on subsequent development of phase 3 studies on the clinical benefit of NMES for rectal cancer patients in the radical pelvic surgery setting.Trial registration: Protocol version 6.0; 05/06/20. ClinicalTrials.govNCT04065984. Registered on 22 August 2019; recruiting.
- 15 September 2021
- Published by Springer Nature in Trials
- Vol. 22 (1) , 1-12
Open AccessBiCyCLE NMES—neuromuscular electrical stimulation in the perioperative treatment of sarcopenia and myosteatosis in advanced rectal cancer patients: design and methodology of a phase II randomised controlled trial
Background: Colorectal cancer is associated with secondary sarcopenia (muscle loss) and myosteatosis (fatty infiltration of muscle) and patients who exhibit these host characteristics have poorer outcomes following surgery. Furthermore, patients, who undergo curative advanced rectal cancer surgery such as pelvic exenteration, are at risk of skeletal muscle loss due to immobility, malnutrition and a post-surgical catabolic state. Neuromuscular electrical stimulation (NMES) may be a feasible adjunctive treatment to help ameliorate these adverse side-effects. Hence, the purpose of this study is to investigate NMES as an adjunctive pre- and post-operative treatment for rectal cancer patients in the radical pelvic surgery setting and to provide early indicative evidence of efficacy in relation to key health outcomes.Method: In a phase II, double-blind, randomised controlled study, 58 patients will be recruited and randomised (1:1) to either a treatment (NMES plus standard care) or placebo (sham-NMES plus standard care) group. The intervention will begin 2 weeks pre-operatively and continue for 8 weeks after exenterative surgery. The primary outcome will be change in mean skeletal muscle attenuation, a surrogate marker of myosteatosis. Sarcopenia, quality of life, inflammatory status and cancer specific outcomes will also be assessed.Discussion: This phase II randomised controlled trial will provide important preliminary evidence of the potential for this adjunctive treatment. It will provide guidance on subsequent development of phase 3 studies on the clinical benefit of NMES for rectal cancer patients in the radical pelvic surgery setting.Trial registration: Protocol version 6.0; 05/06/20. ClinicalTrials.govNCT04065984. Registered on 22 August 2019; recruiting.
- 29 August 2021
- Published by Wiley in Colorectal Disease
- Vol. 23 (11) , 2988-2998
Evolution of the management of retrorectal masses: A retrospective cohort study
Aim: Retrorectal masses are abnormalities located anatomically in the retrorectal space. A significant proportion are asymptomatic with no malignant potential while others cause symptoms due to mechanical pressure or malignant infiltration. We reviewed and categorised the retrorectal masses encountered over a 30‐year time period in a specialist colorectal hospital and describe our management algorithm for consideration by other multidisciplinary teams (MDT).Methods: This was a retrospective analysis of consecutive patients referred between 1984–2019. A detailed review of clinical presentation, imaging features, postoperative histology and impact on morbidity and anorectal function is reported.Results: A total of 143 patients with median age of 46 years and female preponderance (74%) were reviewed. The commonest presenting symptom was pain (46%) and all malignant cases had symptoms (n = 17). Over the last decade, more asymptomatic patients have presented with a retrorectal mass (33%, p = 0.04) and more patients are opting for surveillance rather than resection (33%, p = 0.013). Increasing age and lesion size were associated with malignancy (p < 0.05). Radiological features associated with malignancy included: solid/heterogeneous component, lobulated borders or locally invasive. Following surgery, complications included chronic pain (40%), poor wound healing (23%) and bowel dysfunction (10%).Conclusions: The management of retrorectal masses remains complex. There are features, both clinical and radiological, that can help determine the best management strategy. Management should be in a high‐volume tertiary centre and preferably through a complex rectal cancer MDT. Long‐term sequelae such as chronic pain must be highlighted to patients. We advocate the establishment of an international registry to further record and characterise these rare, potentially troublesome lesions.
- 29 August 2021
- Published by Wiley in Colorectal Disease
- Vol. 23 (11) , 2988-2998
Evolution of the management of retrorectal masses: A retrospective cohort study
Aim: Retrorectal masses are abnormalities located anatomically in the retrorectal space. A significant proportion are asymptomatic with no malignant potential while others cause symptoms due to mechanical pressure or malignant infiltration. We reviewed and categorised the retrorectal masses encountered over a 30‐year time period in a specialist colorectal hospital and describe our management algorithm for consideration by other multidisciplinary teams (MDT).Methods: This was a retrospective analysis of consecutive patients referred between 1984–2019. A detailed review of clinical presentation, imaging features, postoperative histology and impact on morbidity and anorectal function is reported.Results: A total of 143 patients with median age of 46 years and female preponderance (74%) were reviewed. The commonest presenting symptom was pain (46%) and all malignant cases had symptoms (n = 17). Over the last decade, more asymptomatic patients have presented with a retrorectal mass (33%, p = 0.04) and more patients are opting for surveillance rather than resection (33%, p = 0.013). Increasing age and lesion size were associated with malignancy (p < 0.05). Radiological features associated with malignancy included: solid/heterogeneous component, lobulated borders or locally invasive. Following surgery, complications included chronic pain (40%), poor wound healing (23%) and bowel dysfunction (10%).Conclusions: The management of retrorectal masses remains complex. There are features, both clinical and radiological, that can help determine the best management strategy. Management should be in a high‐volume tertiary centre and preferably through a complex rectal cancer MDT. Long‐term sequelae such as chronic pain must be highlighted to patients. We advocate the establishment of an international registry to further record and characterise these rare, potentially troublesome lesions.
- Open Access
- 1 October 2020
- Published by Springer Nature in Research Square
BiCyCLE NMES - Neuromuscular Electrical Stimulation in The Perioperative Treatment of Sarcopenia and Myosteatosis in Advanced Rectal Cancer Patients: Design and Methodology of a Phase II Pilot Study
Background Colorectal cancer is associated with secondary sarcopenia (muscle loss) and myosteatosis (fatty infiltration of muscle) and patients who exhibit these host characteristics have poorer outcomes following surgery. Furthermore, patients who undergo curative advanced rectal cancer surgery such as pelvic exenteration, are at risk of skeletal muscle loss due to immobility, malnutrition and a post-surgical catabolic state. Neuromuscular electrical stimulation (NMES) may be a feasible adjunctive treatment to help ameliorate these adverse side-effects. Hence, the purpose of this study is to investigate NMES as an adjunctive pre- and post-operative treatment for rectal cancer patients in the radical pelvic surgery setting and to provide early indicative evidence of efficacy in relation to key health outcomes. Method In a phase II, Double-blind, randomised controlled study, 58 patients will be recruited and randomised (1:1) to either a treatment (NMES plus standard care) or placebo (sham-NMES plus standard care) group. The intervention will begin two weeks pre-operatively and continue for eight weeks after exenterative surgery. The primary outcome will be change in mean skeletal muscle attenuation, a surrogate marker of myosteatosis. Sarcopenia, quality of life, inflammatory status and cancer specific outcomes will also be assessed. Discussion This pilot study will provide study important preliminary evidence of the potential for this adjunctive treatment. It will provide guidance on subsequent development of phase 3 studies on the clinical benefit of NMES for rectal cancer patients in the radical pelvic surgery setting. Trial Registration ClinicalTrials.gov Identifier: NCT04065984; Registered August 22, 2019; Recruiting.
- 1 October 2020
- Published by Springer Nature in Research Square
Open AccessBiCyCLE NMES - Neuromuscular Electrical Stimulation in The Perioperative Treatment of Sarcopenia and Myosteatosis in Advanced Rectal Cancer Patients: Design and Methodology of a Phase II Pilot Study
Background Colorectal cancer is associated with secondary sarcopenia (muscle loss) and myosteatosis (fatty infiltration of muscle) and patients who exhibit these host characteristics have poorer outcomes following surgery. Furthermore, patients who undergo curative advanced rectal cancer surgery such as pelvic exenteration, are at risk of skeletal muscle loss due to immobility, malnutrition and a post-surgical catabolic state. Neuromuscular electrical stimulation (NMES) may be a feasible adjunctive treatment to help ameliorate these adverse side-effects. Hence, the purpose of this study is to investigate NMES as an adjunctive pre- and post-operative treatment for rectal cancer patients in the radical pelvic surgery setting and to provide early indicative evidence of efficacy in relation to key health outcomes. Method In a phase II, Double-blind, randomised controlled study, 58 patients will be recruited and randomised (1:1) to either a treatment (NMES plus standard care) or placebo (sham-NMES plus standard care) group. The intervention will begin two weeks pre-operatively and continue for eight weeks after exenterative surgery. The primary outcome will be change in mean skeletal muscle attenuation, a surrogate marker of myosteatosis. Sarcopenia, quality of life, inflammatory status and cancer specific outcomes will also be assessed. Discussion This pilot study will provide study important preliminary evidence of the potential for this adjunctive treatment. It will provide guidance on subsequent development of phase 3 studies on the clinical benefit of NMES for rectal cancer patients in the radical pelvic surgery setting. Trial Registration ClinicalTrials.gov Identifier: NCT04065984; Registered August 22, 2019; Recruiting.